{
  "ticker": "ARX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973656",
  "id": "02973656",
  "pages": 7,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0850",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7nxqwnl8061.pdf",
  "summary": "### **June 2025 Quarterly Report (Appendix 4C) Summary**  \n\n#### **Key Financial Highlights:**  \n- **Operating cash flow**: NZ$1.7M (third consecutive positive quarter).  \n- **Cash receipts from customers**: NZ$22.5M (in line with expectations).  \n- **Closing cash balance**: NZ$22.2M (up NZ$0.2M QoQ).  \n- **Debt-free** with NZ$350K unused credit facility.  \n\n#### **Operational Highlights:**  \n- **Myriad\u2122 sales** performing as expected; sustained growth in high-margin products.  \n- **FY26 guidance reaffirmed**: Revenue NZ$92-100M (+10-20% YoY), EBITDA NZ$5-8M (+19-90% YoY).  \n- **Clinical validation**: Two new peer-reviewed studies, including one showing **Endoform\u2122 heals venous leg ulcers ~8 weeks faster** vs. competitor.  \n\nNo material capital-raising, M&A, or liquidity risks identified.",
  "usage": {
    "prompt_tokens": 4197,
    "completion_tokens": 218,
    "total_tokens": 4415,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:01:57.506049"
}